OTC Switch Pathway Abroad Looks Smoother, But Payoffs Are Lower

Switching new Rx drug categories to OTC abroad may appeal to firms put off by the trickle of switches in the U.S., but the payoff abroad is smaller and there is no guarantee FDA will follow another government's decision, experts say

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet